IL157779A0 - Inhibitor of monoamine uptake - Google Patents

Inhibitor of monoamine uptake

Info

Publication number
IL157779A0
IL157779A0 IL15777902A IL15777902A IL157779A0 IL 157779 A0 IL157779 A0 IL 157779A0 IL 15777902 A IL15777902 A IL 15777902A IL 15777902 A IL15777902 A IL 15777902A IL 157779 A0 IL157779 A0 IL 157779A0
Authority
IL
Israel
Prior art keywords
inhibitor
monoamine uptake
monoamine
uptake
Prior art date
Application number
IL15777902A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157779(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL157779A0 publication Critical patent/IL157779A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15777902A 2001-03-06 2002-02-20 Inhibitor of monoamine uptake IL157779A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (1)

Publication Number Publication Date
IL157779A0 true IL157779A0 (en) 2004-03-28

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15777902A IL157779A0 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Country Status (35)

Country Link
US (2) US20040082666A1 (de)
EP (1) EP1379492B1 (de)
JP (1) JP2004525912A (de)
KR (1) KR20030092012A (de)
CN (1) CN1229331C (de)
AP (1) AP2003002855A0 (de)
AT (2) AT414238B (de)
AU (1) AU2002245385B2 (de)
BR (1) BR0207716A (de)
CA (1) CA2440161A1 (de)
CH (1) CH695982A5 (de)
CZ (1) CZ20032380A3 (de)
DE (1) DE60226715D1 (de)
DK (1) DK200301267A (de)
EA (1) EA005768B1 (de)
EC (1) ECSP034760A (de)
EE (1) EE200300419A (de)
ES (2) ES2201942B2 (de)
FI (1) FI20031191A7 (de)
GB (1) GB2389851B (de)
HR (1) HRP20030710A2 (de)
HU (1) HUP0303341A3 (de)
IL (1) IL157779A0 (de)
LT (1) LT5143B (de)
LU (1) LU91038B1 (de)
LV (1) LV13119B (de)
NO (1) NO20033921L (de)
NZ (1) NZ527431A (de)
OA (1) OA12494A (de)
PL (1) PL363840A1 (de)
SE (1) SE526598C2 (de)
SK (1) SK10632003A3 (de)
TR (1) TR200705146T1 (de)
WO (1) WO2002070457A1 (de)
ZA (1) ZA200306882B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030710A2 (en) * 2001-03-06 2004-08-31 Lilly Co Eli Inhibitor of monoamine uptake
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA1327795C (en) * 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
EP1171417B1 (de) 1999-04-09 2005-11-09 Eli Lilly And Company Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
PL366119A1 (en) * 2000-11-15 2005-01-24 Eli Lilly And Company Treatment of anxiety disorders
HRP20030710A2 (en) * 2001-03-06 2004-08-31 Lilly Co Eli Inhibitor of monoamine uptake

Also Published As

Publication number Publication date
DE60226715D1 (de) 2008-07-03
EP1379492B1 (de) 2008-05-21
HUP0303341A2 (hu) 2004-01-28
GB2389851B (en) 2005-05-25
SE0302361L (sv) 2003-09-03
GB0323169D0 (en) 2003-11-05
CZ20032380A3 (en) 2004-03-17
OA12494A (en) 2006-05-24
EA005768B1 (ru) 2005-06-30
LV13119B (en) 2004-06-20
NO20033921L (no) 2003-11-05
US20040082666A1 (en) 2004-04-29
US7384983B2 (en) 2008-06-10
KR20030092012A (ko) 2003-12-03
US20050209341A1 (en) 2005-09-22
TR200705146T1 (tr) 2008-02-21
SE526598C2 (sv) 2005-10-18
AP2003002855A0 (en) 2003-08-20
LT5143B (lt) 2004-06-25
BR0207716A (pt) 2004-03-23
CN1494526A (zh) 2004-05-05
LT2003075A (en) 2004-03-25
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
CN1229331C (zh) 2005-11-30
WO2002070457A8 (en) 2004-06-03
DK200301267A (da) 2003-11-06
EE200300419A (et) 2004-02-16
EA200300978A1 (ru) 2004-02-26
WO2002070457A1 (en) 2002-09-12
NO20033921D0 (no) 2003-09-04
AU2002245385B2 (en) 2007-01-18
CH695982A5 (de) 2006-11-15
ATE396170T1 (de) 2008-06-15
ZA200306882B (en) 2004-12-03
JP2004525912A (ja) 2004-08-26
GB2389851A (en) 2003-12-24
LU91038B1 (fr) 2003-09-11
ES2305221T3 (es) 2008-11-01
CA2440161A1 (en) 2002-09-12
ES2201942B2 (es) 2004-12-16
EP1379492A1 (de) 2004-01-14
AT414238B (de) 2006-10-15
FI20031191L (fi) 2003-08-25
ATA90422002A (de) 2006-01-15
FI20031191A7 (fi) 2003-08-25
SE0302361D0 (sv) 2003-09-03
ES2201942A1 (es) 2004-03-16
PL363840A1 (pl) 2004-11-29
NZ527431A (en) 2005-05-27
ECSP034760A (es) 2003-10-28
SK10632003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
HUP0600294A2 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition
GB0125445D0 (en) Protease Inhibitors
IL157657A0 (en) Metalloproteinase inhibitors
IL157570A0 (en) Metalloproteinase inhibitors
IL157658A0 (en) Metalloproteinase inhibitors
IL160819A0 (en) Novel compounds and compositions as cathepsin inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
AU2003290735A8 (en) Inhibitors of monoamine uptake
GB2389851B (en) Inhibitor of monoamine uptake
GB2380200B (en) Photoluminescent compounds
AU2002360673A8 (en) Gp41 inhibitor
SG119168A1 (en) Utilization of at least one aminopeptidase inhibitor
EP1401453A4 (de) Proteasehemmer
HUP0303185A3 (en) Glyt-1 inhibitors
GB0228482D0 (en) Inhibitors of monoamine uptake
GB0314414D0 (en) Inhibitors of monoamine uptake
GB0128453D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors
GB0101135D0 (en) Inhibitors
HRP20031092A2 (en) Novel compounds and compositions as cathepsin inhibitors
GB0100485D0 (en) Corrosion inhibitors
GB0121073D0 (en) Inhibitors of complement activation
GB0210427D0 (en) Calmag - magnetic in-line scale inhibitor
GB0210428D0 (en) Calmag JG - magnetic in-line pushfit scale inhibitor
GB0210426D0 (en) Caltronic - electronic scale inhibitor